Moreover, a number of MEF2 targets have been identified, namely related to cancer (e.g., MYC, TGFB1, CARD11, RHOB, and NDRG1) [21], and particularly with sprouting angiogenesis in tumor vascularization (e.g., Delta-like ligand 4, Dll4) [22]. This evidence concerns the gene DLL4 and cancer.